PubMed Health⌕ Search

Biomedical subjects

R S Root-Bernstein

Publications and source records attributed to R S Root-Bernstein.

At least 19 recordsLinked to original sources
PubMed1990

Peptide displacement of [3H]5-hydroxytryptamine binding to bovine cortical membranes.

Chemical studies have demonstrated that peptides such as the encephalitogenic (EAE) peptide of myelin basic protein (MBP) and luteinizing hormone-releasing hormone (LHRH) can bind serotonin (5-hydroxytryptamine, 5-HT) in vitro. The present research was undertaken to determine whether such binding interferes with 5-HT binding to its 5-HT1 receptors on bovine cerebral cortical membranes. EAE peptide and LHRH displaced [3H]5-HT with IC50s of 4.0 x 10(-4) and 1.8 x 10(-3) M respectively. MBP itself also showed apparent displacing ability with an IC50 of 6.0 x 10(-5) M, though it also caused aggregation of cortical membranes that might have interfered with normal receptor binding. These results support previous suggestions that the tryptophan peptide region of MBP may act as a 5-HT receptor in the neural system. We also tested the effects of muramyl dipeptide (N-acetyl-muramyl-L-Ala-D-isoGln, MD), a bacterial cell-wall breakdown product that acts as a slow-wave sleep promoter, binds to LHRH and EAE peptide, and competes for 5-HT binding sites on macrophages. It showed no significant displacement of 5-HT binding to cortical membranes (IC50 greater than 10(-1) M), but its D-Ala analogue did (IC50 = 1.7 x 10(-3) M). Thus, it seems likely that the 5-HT-related effects of naturally occurring muramyl peptides are physiologically limited by receptor types.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1990

Serotonin binding sites. II. Muramyl dipeptide binds to serotonin binding sites on myelin basic protein, LHRH, and MSH-ACTH 4-10.

Previously, we reported the existence of structurally similar serotonin binding sites on myelin basic protein, LHRH, and MSH-ACTH 4-10. We now report that the adjuvant peptide, muramyl dipeptide (N-acetyl-muramyl-L-Ala-D-isoGln) also binds to these sites. This observation may help to explain previous observations of serotonin-like activity by muramyl peptides, including the promotion of slow-wave sleep and fever induction. The observation may also provide an important link between the immune system and the nervous system that may explain the role of muramyl dipeptide adjuvants in causing autoimmune diseases to serotonin-regulated proteins and their receptors, as well as the alterations in serotonin levels that are often observed in autoimmune diseases. The observation provides concrete evidence for a dual-antigen hypothesis for the induction of autoimmune diseases by an adjuvant-peptide complex. Application of such a mechanism for induction of autoimmunity may be of importance in understanding a number of postinfectious and postvaccinal neuropathies, and suggests a possible etiology for autism, in which many patients have high blood serotonin levels, autoimmune reactions to myelin basic protein, and antibodies to serotonin binding sites. Finally, the observation suggests that glycopeptides may act as neurotransmitters.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1987

Catecholamines bind to enkephalins, morphiceptin, and morphine.

Nuclear magnetic resonance spectroscopy, pH titration, and color reactions demonstrate that the catecholamines dopamine, epinephrine, and norepinephrine bind to the enkephalins. Binding constants are c. 6 X 10(3) per mole. Catecholamines also bound to the mu opiate receptor agonist morphiceptin (Tyr-Pro-Phe-Pro-NH2). Very little binding was found to enkephalin and morphiceptin fragments and analogues, indicating that the entire molecules are necessary. Serotonin binding peptides do not bind the catecholamines. Morphine and apomorphine, however, do bind these catecholamines (with a binding constant for morphine of c. 4 X 10(4) per mole). The opiate antagonist naloxone and a number of other drugs do not bind catecholamines. Morphine, morphiceptin, and the enkephalins also retard the formation of colored reaction products by catecholamines in vitro. These results may help to explain observations that the enkephalins are co-stored and co-transmitted with dopamine and norepinephrine, and may provide a basis for the elucidation of other known cases of peptide-monoamine co-transmission. Possible implications for understanding opiate effects on catecholamines during addiction and withdrawal are discussed, and suggestions concerning drug design are made.

Catecholamines↗
PubMed1987

Harmony and beauty in medical research.

We too often report the results of biomedical research as if there were no people involved in producing those results. However, without physicians and PhD's there would be no medical research. Moreover, reference to the history of medicine and science reveals that very often the men and women who have created the most important medical breakthroughs and perceived the most significant facts of medicine have also been unusually talented in other disciplines as well: music, the arts, poetry and literature. I do not believe that this correlation of talents is an accident. Rather, I argue that the kind of medicine and science that a person accomplishes is a reflection of the personality and skills that the person brings to his or her work. Thus, those doctors who have been most sensitive to their culture, and most inventive in their everyday lives, have also been the most insightful and original in their work. Music, the arts, poetry, and literature actually contribute in essential ways to the training of eminent doctors, and influence the way in which they perceive medicine. I therefore argue that it is not enough that we do our utmost to push back the veils of ignorance in our clinics and laboratories: we must also begin to push back the veils of ignorance that surrounds the questions of who does the best biomedical research and why. We must recognize the intricate ways in which the who, the how, and the what of research are inextricably entwined.

Art↗
PubMed1986

Clinical suppression of experimental allergic encephalomyelitis by muramyl dipeptide "adjuvant".

Experimental allergic encephalomyelitis (EAE) is a model for several human diseases including multiple sclerosis and post-vaccinal encephalopathies. EAE is generally thought to be an autoimmune response to the antigen myelin basic protein (MBP). Oddly, MBP can also suppress EAE, and many observations suggest that an independent immune response to so-called "adjuvant" material is also necessary to EAE induction. Thus, EAE may be a result of a pair of interactive immune responses, one against MBP, and one against adjuvant. If so, the adjuvant should, like MBP, suppress EAE. We present data from experiments on strain 13 guinea pigs demonstrating EAE suppression by muramyl dipeptide, an active component of complete Freund's adjuvant. These results are striking because classically adjuvants are defined as immunopotentiators, not immunosuppressants. Our results, therefore, suggest that a revaluation of the role of adjuvants in inducing autoimmune diseases may be necessary.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1986

Bovine pineal antireproductive tripeptide binds to luteinizing hormone-releasing hormone: a model for peptide modulation by sequence specific peptide interactions?

We report results of chromatographic, pH titration and nuclear magnetic resonance (NMR) spectroscopy studies demonstrating that the bovine pineal antireproductive tripeptide, Thr-Ser-Lys (BPART), binds to luteinizing hormone-releasing hormone (LHRH) at a site comprised of LHRH 2-5 (His-Trp-Ser-Tyr). BPART and LHRH have been shown to be antagonists in vitro. The binding constant is ca. 2 X 10(3)/mole. An NMR study of fifty other peptide pairs demonstrates that the binding is sequence and residue specific. The binding provides evidence of the amino acid pairing hypothesis, and suggests the possibility of modulation of one peptide by directly binding with another peptide.

Amino Acid Sequence↗
PubMed1984

'Molecular sandwiches' as a basis for structural and functional similarities for interferons, MSH, ACTH, LHRH, myelin basic protein, and albumins.

Sequential similarities between the tryptophan peptide of myelin basic protein (residues 111-121), luteinizing hormone releasing hormone, melanotropin, adrenocorticotropin (residues 1-13), human leukocyte interferon (residues 28-40), and various segments of human and bovine serum albumin and hen ovalbumin are presented. It is suggested that these structural similarities may explain observations concerning common functional characteristics such as serotonin modulation, immunological activity with the adjuvant muramyl dipeptide, immunological cross-reactivity, and the possible MSH-ACTH-like activity of a pepsin-derived peptide of interferon.

Adrenocorticotropic Hormone↗
PubMed1984

Serotonin binding sites. I. Structures of sites on myelin basic protein, LHRH, MSH, ACTH, interferon, serum albumin, ovalbumin and red pigment concentrating hormone.

We report the results of nuclear magnetic resonance spectroscopy studies of combinations of serotonin (5-hydroxytryptamine) with the tryptophan peptide sequence and similar peptides from myelin basic protein. The binding site appears to consist of the sequence Arg Phe Ser Trp. Similar serotonin binding sites were found to exist on LHRH (Tyr Ser Trp) and MSH-ACTH tetrapeptide (Phe Arg Trp). These binding sites are specific to serotonin as is demonstrated by lack of binding by dopamine, histamine, acetylcholine and a dozen other pharmacologically active amines and indoles. Drugs known to affect serotonin levels, e.g., fenfluramine and L-DOPA, bind weakly to these sites. Structural and functional similarities between the tryptophan peptide, LHRH, and MSH-ACTH with an ACTH-like peptide of human leukocyte interferon, with human and bovine serum albumin, hen ovalbumin, and with red pigment concentrating hormone suggest that the latter peptides may also contain similar serotonin binding sites. The elucidation of serotonin binding sites on these peptides and proteins has implications for understanding various aspects of cancer, autoimmunity, neurological disease, and peptide hormone control.

Adrenocorticotropic Hormone↗
PubMed1984

Fenfluramine binds 5-hydroxytryptophan.

Fenfluramine, an anorexigenic drug, lowers serotonin (5-hydroxytryptamine) and 5-hydroxyindoleacetic acid levels in brain, spinal fluid, and blood, and has been used as a treatment for autism. Fenfluramine's mode of action is unknown. We present evidence from chromatography and nuclear magnetic resonance spectroscopy that fenfluramine selectively binds the serotonin and 5-hydroxyindoleacetic acid precursor, 5-hydroxytryptophan. The mode of binding may have general applications for the understanding of drug activity, receptor binding, and for the design of specific antagonists to aromatic compounds.

5-Hydroxytryptophan↗
PubMed1983

The structure of a serotonin and LSD binding site of myelin basic protein.

Experiments have established the presence of a serotonin binding site in the tryptophan region of myelin basic protein. LSD competes for this binding site in vivo and in vitro. Although previous models have been suggested for the site, these models failed to explain the results of serotonin modification studies or the mode of LSD binding to the site. A new model of the site is proposed to rectify these problems. Means of testing the model are suggested. Implications for understanding neuroreceptor physiology, specificity, and disease are discussed. The name "molecular sandwiching" is suggested to describe the binding process.

Binding Sites↗
PubMed1983

An explanation of prevention and suppression of experimental allergic encephalomyelitis.

An explanation of experimental allergic encephalomyelitis prevention and suppression is presented based upon evidence that the active unit in disease induction is an encephalitogen-adjuvant complex. The stereochemical complementarity in structure of the encephalitogen and adjuvant is mirrored in complementarity in the recognition sites of lymphocyte populations activated against encephalitogen and adjuvant. Since two complementary lymphocyte populations are necessary for disease induction, any procedure that prevents the development of one of these populations will prevent disease induction. Any procedure that eliminates one population after induction has occurred will suppress the disease. We argue that all extant data support the hypothesis. Several new experiments are proposed to further test it.

Adjuvants, Immunologic↗